



2022 **ANNUAL** *REPORT*

Dear Reader,

We are so proud of the work Whitman-Walker was able to do for community and staff in 2022. Our goal as leaders was to focus on our mission; to make sure that Whitman-Walker is an inclusive space for everyone; and to ensure that we remain financially responsible stewards ready to see even more patients and host more research when we open the doors of our new Max Robinson Center in 2023.

In 2022, we launched an Equity and Belonging Committee that resulted in a first-ever Board endorsed road map for our future of equity and belonging. We are proud of this employee-led and employee-developed work product. They were courageous, thoughtful and comprehensive and they delivered a plan that will be critical to future growth and as a regional and national leader in care, advocacy, education, and research.

Even in a year that continued to have some remarkable public health obstacles, our Whitman-Walker Health team was able to deliver on its mission of excellent care and services to over 16,000 community members, amid new COVID related changes and a surge in a new under-resourced disease, Mpox. Additionally, the Whitman-Walker Health team was repositioned as leaders in the Connected Care Network, the FQHC collaboration to deliver value-based care to Medicaid managed care organizations and we secured \$3.42 million in new grants exceeding our goal by nearly three-fold.

The Whitman-Walker Institute team secured multiple new grants including a \$2 million grant from NIH to help build out a state-of-the-art research facility at our new MRC and an NIH grant in partnership with GW to launch a nationwide cohort to study how state-level policy and climate in the form of structural racism and anti-LGBTQ stigma are associated with HIV inequities for LGBTQ+ people of color. The policy and advocacy team continued work on several policy goals informed by the needs of the patients and communities that we serve including advancing health equity in federal policy for LGBTQI+ communities, protecting access to gender-affirming care for transgender people nationwide, and promoting LGBTQI+ cultural competency in the health care workforce. Our policy team received two six-figure project grants and three five-figure general policy grants, an unprecedented number that went a long way in furthering our policy work.

Our Foundation team also garnered another \$1 million gift from Gilead Sciences for our new Max Robinson Center expansion and successfully raised over \$600,000 from community and sponsorships through our annual Walk to End HIV event.

Additionally, we were able to gather with more in person events and we ended our year with a moving tribute to our community with a World AIDS Day event in The Corner to honor those we've lost to HIV and to celebrate the future of HIV research.

Thank you for your support for an amazing year. Our success and our goals to become an even more equitable organization can only be realized through your support and generosity. We are so excited to see what 2023 has in store.



Naseema Shafi, CEO
Whitman-Walker Health



Ryan Moran, CEO
Whitman-Walker Health System

BOARD OF DIRECTORS

Whitman-Walker Health

Natasha Bonhomme She/Her	Travis Patton He/Him	Diego Mariscal He/Him
Derrick "Strawberry" Cox He/Him	Frances Reed They/Them	Shannon White She/Her
Harry Fox He/Him	Jimmy Rollins He/Him	lisa wise She/Her
Stephanie Hales She/Her	Keven Semelrath He/Him	J Jenkins They/Them
Sandy James He/Him	Chip Sherrill He/Him	Haywood Perry He/Him

Whitman-Walker Health System

Ann Bonham She/Her	Andre Eleazer He/Him	Tom Peterson He/Him
Natasha Bonhomme She/Her	Harry Fox He/Him	Matt Voohrees He/Him
Glynda Brown She/Her	Jennifer Kates She/Her	lisa wise She/Her
Jehan "Gigi" El-Bayoumi, MD She/Her	Travis Patton He/Him	


Whitman-Walker Foundation

Glynda Brown She/Her	Cary Hatch She/Her	Tom Peterson He/Him
June Crenshaw She/Her	Harry Fox He/Him	Matt Voohrees He/Him
Tim Ehrlich He/Him	Jennifer Kates She/Her	
Jack Gocke He/Him	Travis Patton He/Him	


Whitman-Walker Institute

Jehan "Gigi" El-Bayoumi, MD She/Her	Jen Kates She/Her
Alison Gill She/Her	Gregorio Millet He/Him


PATIENT DEMOGRAPHICS




PATIENT LOCATION




SEXUAL ORIENTATION




HIV RELATED CARE




IDENTIFY AS TRANSGENDER




GENDER IDENTITY




PATIENTS BY AGE




HOUSING STATUS



LANGUAGE



INSURANCE



TELEHEALTH

HIGHLIGHTS

WHITMAN-WALKER IN THE COMMUNITY



GOING THE EXTRA MILE


May 19, 2022



RECOVERY HARDWARE

BOOK SIGNING WITH GINA SCHAEFER

September 13, 2022



RYAN MORAN WELCOMES YOU TO WHITMAN-WALKER

September 15, 2022



WALK TO THE END HIV

October 22, 2022

Adherence 2022 Navigating the Future of HIV

NOVEMBER 7-9, 2022 • WASHINGTON, DC

DR. SARAH HENN PRESENTS THE
MEMORIAL LECTURE AT THE
ADHERENCE 2022 CONFERENCE:
INNOVATIONS IN HIV

November 8, 2022



WORLD AIDS DAY CANDLELIGHT VIGIL

December 1, 2022



HHS SECRETARY DISCUSSES
FEDERAL OVERDOSE PREVENTION
EFFORTS AT WHITMAN-WALKER

December 3, 2022

INSTITUTE *HIGHLIGHTS*

Whitman-Walker Institute secured an unprecedented (for a community health center) \$2 million construction grant from NIH to support the building of a cutting-edge biomedical HIV research facility as part of our Max Robinson Center on the new St. Elizabeth's campus.



Whitman-Walker Institute launched a new internship program and brought on Dr. Jowanna Malone as a research scientist and Dr. Rupa Patel as a clinical scientist to broaden and strengthen our position as a leader in community-engaged HIV and LGBTQ+ health research. It also launched an affiliated investigator program with George Washington University to expand opportunities to explore a range of clinical and applied research issues, including women's health, mental health, and cancer.



Whitman-Walker Institute was especially proud to put its first two patients on injectable HIV and PrEP treatments. They have both been a huge team lift and are a major advance.



2022 FINANCIALS



Consolidated Statements of Financial Position

Current Assets

Cash and cash equivalents	\$10,418,884
Accounts receivable:	
Grants and contracts	\$2,146,411
Medicaid and other third parties, net	\$2,146,736
Pharmacy, net	\$3,950,073
Other	\$92,967
Inventory	\$1,747,194
Prepaid expenses	\$845,657
 Total current assets	 \$21,347,922
 Related entity receivable, net	 \$3,935,268
Property and equipment, net	\$14,599,990
Restricted cash in escrow	\$4,000,000
Right-of-use asset	\$86,841,859
Other assets	\$432,145
 Total assets	 \$131,157,184

Current liabilities

Account payable and accrued expenses	\$11,626,926
Loan payable	\$2,000,000
Deferred revenue	\$1,086,215
Lease liability, current portion	\$4,931,943
Deferred rent, current portion	-
Due to third party	\$3,366,437
 Total current liabilities	 \$23,011,521

Long-term liabilities

Related entity payable, net of current portion	\$1,000,000
Lease liability, net of current portion	\$86,761,122
Deferred rent, long-term portion	-
Total liabilities	\$110,772,643

Commitments and contingencies (Note 9 and 10)

Net assets

Without donor restrictions	\$108,071
Board-designated	\$20,276,470
Undesignated	
 Total net assets	 \$20,384,541
Total liabilities and net assets	\$131,157,184

2022 FINANCIALS

Consolidated Statements of Financial Position

Assets

Cash and cash equivalents	\$10,418,884
Grants and contributions receivable, current portion	
Clinical research trails receivable	\$2,146,411
Other current assets	\$2,146,736
Total current assets	\$3,950,073
	\$92,967
Accrued interest receivable	\$1,747,194
Property and equipment, net	\$845,657
Refundable security deposit, related party	
Right-of-use assets	\$21,347,922
Investment in joint venture	
	\$3,935,268
Total assets	\$14,599,990
	\$4,000,000
	\$86,841,859
	\$432,145

Liabilities and net assets (deficit)

\$131,157,184

Current liabilities

Accounts payable and accrued expenses	\$1,538,289
Deferred revenue	\$655,467
Current portion of lease liability	\$1,047,920
Due to related party	-
Total current liabilities	\$3,241,676

Long-term liabilities

Due to related party	\$4,069,285
Notes payable	\$6,642,691
Lease Liability, net of current portion	\$36,124,712

Total liabilities \$50,078,364

Net assets (deficit)

Without donor restrictions:	(\$3,453,485)
Operations	(\$222,952)
Real Property Holdings	(\$3,676,437)

With donor restrictions \$602,374

Total net deficit (\$3,074,063)

Total liabilities and net deficit \$47,004,301